In cohort D of the CHRYSALIS-2 study, the combination therapy of amivantamab and lazertinib reported an ORR of 61% and mPFS of 12.2 months in patients with MET-positive (MET 3 or higher staining in ≥25% tumor cells) EGFR-mutant NSCLC progression on osimertinib.29 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.